Illinois Senate Bill SB3727

Illinois 2023-2024 Regular Session

• Introduced: 2/9/24
• Refer: 2/9/24

Caption

PATIENT ACCESS 340B PHARMACY

Impact

The legislation introduces significant changes to how pharmaceutical distribution is regulated in Illinois. It explicitly prohibits any entity, including pharmaceutical manufacturers, from denying or limiting the acquisition and delivery of 340B drugs to covered entities or their contract pharmacies. This could potentially increase the availability of affordable medications for underserved populations, thus promoting healthcare equity. The bill also outlines enforcement mechanisms and establishes the Department of Financial and Professional Regulation as the body responsible for overseeing compliance with these new regulations.

Summary

SB3727, known as the Patient Access to Pharmacy Protection Act, aims to ensure that 340B covered entities and their designated contract pharmacies can acquire and deliver 340B drugs without interference from drug manufacturers. The bill highlights the challenges faced by residents, especially in rural and medically underserved areas, in accessing life-saving medications due to restrictions imposed by manufacturers on the distribution of drugs purchased under the federal 340B drug discount program. As such, the Act reinforces the authority of the State to regulate these transactions and facilitates improved healthcare access for its citizens.

Contention

While the bill aims to enhance access to essential medications, there may be concerns regarding its implications on pharmaceutical manufacturers and their operational frameworks. Some stakeholders might argue that the provisions could lead to operational disruptions for manufacturers or might complicate existing distribution practices. Moreover, there could be discussions around how these changes would interact with federal laws governing pharmaceutical distribution, especially concerning compliance and auditing requirements for 340B entities.